Post-market Safety Reassessment of Ulinastatin for Injection
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
1. Investigate the application of ulinastatin(UTI) in real practice clinic.(eg:population
character, usage and dosage, course of treatment,etc )
2. Analysis the incidence of adverse drug reactions /adverse events of ulinastatin, collect
the main clinical manifestations, treatment, outcome, influence factors; provide
evidence for improving the recommended medication plan of ulinastatin.
3. Evaluate the safety of ulinastatin , obtain scientific conclusion , and provide evidence
for appropriate medication to administration department of health authority.
Details
Lead Sponsor:
Techpool Bio-Pharma Co., Ltd.
Collaborators:
Center for ADR Monitoring of Guangdong Center for Adverse Drug Reaction Monitoring of Guangdong